Abbott's $385M Formula Plant Deal Resolves DOJ and Qui Tam Claims

For in-house counsel and regulatory litigators, Abbott's $385 million Sturgis formula settlement is a case study in parallel risk: a DOJ civil lawsuit, qui tam relators, and multiple state Attorneys General all converged on one plant shutdown. The company's no-liability framing while paying nine figures underscores how settlements manage criminal, civil, and reputational exposure simultaneously.

Abbott Laboratories has agreed to pay $385 million to resolve claims tied to the contamination investigation at its Sturgis, Michigan, infant formula plant, the largest in the United States. The settlement, announced Monday, September 14, 2026, resolves a lawsuit by the Justice Department and lawsuits filed by certain relators and the Attorneys General of several states. The amount is substantial, yet Abbott is explicit that the agreement does not represent any finding of fault or liability. That distinction is the legal crux of the matter: the company has bought closure across multiple civil and quasi-criminal fronts while preserving its ability to argue that no contaminated product was ever distributed.

“

For in-house counsel and regulatory litigators, Abbott's $385 million Sturgis formula settlement is a case study in parallel risk: a DOJ civil lawsuit, qui tam relators, and multiple state Attorneys General all converged on one plant shutdown.

The Sturgis plant was at the center of the 2022 formula crisis. Abbott closed the facility in February 2022 after the FDA began an investigation, and the company recalled powdered infant formula brands including Similac. That recall removed critical inventory from a market already strained by supply chain disruptions and pandemic stockpiling. The Biden administration responded with unusual emergency measures: it eased import rules for foreign manufacturers, airlifted formula from Europe, and invoked federal emergency rules to prioritize U.S. production. The plant reopened by June 2022, but the legal fallout continued for more than four years.

For legal audiences, the settlement's structure is more revealing than the dollar figure. A $385 million payment is far from nominal, suggesting that the evidence or litigation risk was serious enough to justify a nine-figure resolution. Yet Abbott's statement that government tests of unopened product from the homes of infants under investigation at the time of the 2022 recall were negative for Cronobacter sakazakii indicates the company retained a factual defense: no unopened distributed Abbott infant formula has ever tested positive for the bacterium. This is a critical nuance. In food and drug safety litigation, a negative test result from sealed product can blunt causation and damages theories, even when contamination is suspected in the broader facility environment.

The presence of relators also points to qui tam litigation, the statutory mechanism through which whistleblowers can pursue False Claims Act or similar fraud claims on behalf of the government. State Attorneys General lawsuits add another layer of exposure, potentially involving consumer protection, Medicaid fraud, or public nuisance theories. Resolving all of these claims in a single settlement avoids separate trials, contradictory rulings, and prolonged discovery. The Justice Department under President Donald Trump closed its criminal investigation, a sign that federal prosecutors did not believe they could meet the beyond-a-reasonable-doubt standard or lacked sufficient evidence of mens rea. That does not extinguish civil liability, where burdens are lower and regulatory violations can still yield large monetary settlements.

From a corporate law perspective, Abbott's outcome illustrates how a single operational failure at a single plant can metastasize into federal, state, and qui tam exposure. The settlement likely includes no admission of liability, which protects Abbott against follow-on private litigation, FDA debarment, and licensing or contracting exclusions. But the price of that non-admission was high, and state AG settlements often include injunctive terms requiring compliance program changes, reporting obligations, or future monitoring. In that sense, $385 million buys finality but not necessarily operational freedom.